<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tutik Sri Wahyuni</style></author><author><style face="normal" font="default" size="100%">Adita Ayu Permanasari</style></author><author><style face="normal" font="default" size="100%">Lidya Tumewu</style></author><author><style face="normal" font="default" size="100%">Aty Widyawaruyanti</style></author><author><style face="normal" font="default" size="100%">Achmad Fuad Hafid</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Qualitative and Quantitative Analysis of 70% Ethanol Extract from Ruta angustifolia for Developing Anti-Hepatitis C Agents</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Hepatitis C Virus</style></keyword><keyword><style  face="normal" font="default" size="100%">Infectious disease</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicinal plants</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicine</style></keyword><keyword><style  face="normal" font="default" size="100%">Ruta angustifolia</style></keyword><keyword><style  face="normal" font="default" size="100%">Rutin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2021</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2021</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">682-687</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Medicinal plants are potential sources for drug candidates. It possesses with various metabolites which have many pharmacology effects. &lt;em&gt;Ruta angustifolia&lt;/em&gt; is one of medicinal plants that has been used traditionally for liver disease. Previous study it has been demonstrated to inhibit hepatitis C virus under in vitro cell culture. It decreased protein NS3 level and gave synergistic effect in combination with simeprevir and telaprevir. This plant provides a prospective candidate to develop as anti-HCV Objective: This study evaluates the phytochemistry screening for qualitative assay and determine the concentration of rutin as marker compound for developing &lt;em&gt;R. angustifolia&lt;/em&gt; extract as anti-HCV agent.&lt;strong&gt; Materials and Methods:&lt;/strong&gt; &lt;em&gt;R. angustifolia&lt;/em&gt; leaves were extracted with 70% of ethanol. Extract and rutin were analysis their anti-HCV activity by in vitro culture cells of Huh7it. The concentration of rutin was determine by TLC densitometry. &lt;strong&gt;Results:&lt;/strong&gt; The 70% ethanol extract of &lt;em&gt;R. angustifolia &lt;/em&gt;dan rutin exhibit anti-HCV activities with IC&lt;sub&gt;50&lt;/sub&gt; value of 2.9 ± 0.8 μg/ml and 28.1 ± 5.6 μg/ml, respectively. Screening phytochemistry demonstrated to contain flavonoid, terpenoid, alkaloid and polyphenols. TLC densitometry analysis yield the concentration of rutin in extract 0.06 %. &lt;strong&gt;Conclusion:&lt;/strong&gt; Extract of 70% ethanol of &lt;em&gt;R. angustifolia &lt;/em&gt;has a potential anti-HCV activity. Extract of &lt;em&gt;R. angustifolia&lt;/em&gt; may provide a good candidate for developing anti-HCV agents.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">682</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Tutik Sri Wahyuni&lt;sup&gt;1,2,&lt;/sup&gt;*, Adita Ayu Permanasari&lt;sup&gt;2&lt;/sup&gt;, Lidya Tumewu&lt;sup&gt;2&lt;/sup&gt;, Aty Widyawaruyanti&lt;sup&gt;1,2&lt;/sup&gt;, Achmad Fuad Hafid&lt;sup&gt;1,2&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmaceutical Science, Faculty of Pharmacy, Universitas Airlangga, Jl. Mulyorejo, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Center of Natural Product Medicine Research and Development, Institute of Tropical Disease, Universitas Airlangga, Jl. Mulyorejo, Surabaya 60115, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dwi Susiloningrum</style></author><author><style face="normal" font="default" size="100%">Adita Ayu Permanasari</style></author><author><style face="normal" font="default" size="100%">Myrna Adianti</style></author><author><style face="normal" font="default" size="100%">Lidya Tumewu</style></author><author><style face="normal" font="default" size="100%">Tutik Sri Wahyuni</style></author><author><style face="normal" font="default" size="100%">Mulyadi Tanjung</style></author><author><style face="normal" font="default" size="100%">Aty Widyawaruyanti</style></author><author><style face="normal" font="default" size="100%">Achmad Fuad Hafid</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">The Alkaloid Fraction from Melicope latifolia Leaves Inhibits Hepatitis C Virus</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Anti-HCV</style></keyword><keyword><style  face="normal" font="default" size="100%">Melicope latifolia</style></keyword><keyword><style  face="normal" font="default" size="100%">N-methylflindersine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">535-540 </style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Hepatitis C Virus (HCV) is a major health problem, which infects approximately 170 million people among worldwide population. Moreover, there is no vaccine available to prevent HCV infection and the current anti-HCV drugs have not covered all the various genotypes and subtypes. Meanwhile, medicinal plants have been widely used to treat a variety of infectious disease. Our previous study reported that ethanol extract of &lt;em&gt;Melicope latifolia &lt;/em&gt;has been shown to exert anti-HCV activity towards a number of different virus genotypes with mainly inhibition mechanism at the entry step. Further separation was needed to purify and identify the active anti-HCV constituent using bioactivity-guided isolation method.&lt;strong&gt; Materials and Methods:&lt;/strong&gt; &lt;em&gt;In vitro&lt;/em&gt; Anti-HCV assay was performed using hepatocyte cell line (Huh7it) and HCV genotype 2a (JFH1). The purification of &lt;em&gt;M. latifolia &lt;/em&gt;ethanol extract (B1F) was done by liquid-liquid fractionation, vacuum liquid chromatography (VLC), and high-performance liquid chromatography (HPLC). The active fraction was further identified by thin layer chromatography (TLC) and the major constituent was determined by nuclear magnetic resonance (NMR) spectra data analysis. &lt;strong&gt;Results: &lt;/strong&gt;The fractionation of &lt;em&gt;M. latifolia&lt;/em&gt; leaves ethanol extract resulted an alkaloid fraction (B1F D2H.3) containing a major constituent N-methylflindersine. This alkaloid fraction was active to reduce HCV JFH1 with an inhibition concentration (IC&lt;sub&gt;50&lt;/sub&gt;) value of 6.21 µg/mL, a cytotoxicity concentration (CC&lt;sub&gt;50&lt;/sub&gt;) value of 82.64 µg/mL, and a selectivity index value of 13.31. &lt;strong&gt;Conclusion: &lt;/strong&gt;An alkaloid fraction of &lt;em&gt;M. latifolia&lt;/em&gt; (B1F D2H.3) was known to have major compound named N-methylflindersine. This alkaloid fraction exhibited strong anti-HCV against JFH1 &lt;em&gt;in vitro&lt;/em&gt;. The results indicated that this alkaloid fraction may a good candidate for anti-HCV agent.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">535</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Dwi Susiloningrum&lt;sup&gt;1&lt;/sup&gt;, Adita Ayu Permanasari&lt;sup&gt;2&lt;/sup&gt;, Myrna Adianti&lt;sup&gt;2,3&lt;/sup&gt;, Lidya Tumewu&lt;sup&gt;2&lt;/sup&gt;, Tutik Sri Wahyuni&lt;sup&gt;2,4&lt;/sup&gt;, Mulyadi Tanjung&lt;sup&gt;2,5&lt;/sup&gt;, Aty Widyawaruyanti&lt;sup&gt;2,4&lt;/sup&gt;, Achmad Fuad Hafid&lt;sup&gt;2,4&lt;/sup&gt;,* &lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Graduate Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Natural Product Medicine Research and Development, Institute of Tropical Disease, Universitas Airlangga, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Health, Traditional Medicine Study Program, Faculty of Vocational, Universitas Airlangga, Surabaya 60286, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Chemistry, Faculty of Science and Technology, Universitas Airlangga, Surabaya 60115, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Tutik Sri Wahyuni</style></author><author><style face="normal" font="default" size="100%">Adita Ayu Permanasari</style></author><author><style face="normal" font="default" size="100%">Aty Widyawaruyanti</style></author><author><style face="normal" font="default" size="100%">Hak Hotta</style></author><author><style face="normal" font="default" size="100%">Chie Aoki-Utsubo</style></author><author><style face="normal" font="default" size="100%">Achmad Fuad Hafid</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Antiviral Activity of Indonesian Medicinal Plants against Hepatitis B Virus</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Curcuma xanthorhiza</style></keyword><keyword><style  face="normal" font="default" size="100%">Hepatitis B Virus</style></keyword><keyword><style  face="normal" font="default" size="100%">Medicinal plants</style></keyword><keyword><style  face="normal" font="default" size="100%">Phyllanthus niruri</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">1108-1114</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background: &lt;/strong&gt;Hepatitis B virus (HBV) infects more than 300 million people globally and is a common cause of liver cancer. Current therapy using reverse transcriptase inhibitors require long-term treatment and the potential risk of development of drug-resistant viruses remains an important issue to be considered. Hence, the development of new drugs is critical. Traditional medicinal plants used for the treatment of infectious diseases may provide a viable option for the discovery of anti-HBV drug candidates. &lt;strong&gt;Objective: &lt;/strong&gt;This study examined anti-HBV activity of 31 kinds of Indonesian plants. &lt;strong&gt;Materials and Methods: &lt;/strong&gt;Crude extracts of various part of plants, leaves and stem, were obtained using dichloromethane and ethanol solvent. The effect on viral entry was examined by determining levels of HBsAg expression in the supernatants of HBV-infected HepG2-NTCP cells by ELISA. The effect on HBV replication was determined by measuring HBV DNAs amounts in Hep38.7-Tet cells by quantitative real-time PCR.&lt;strong&gt; Results: &lt;/strong&gt;The extracts of &lt;em&gt;Phyllantus niruri&lt;/em&gt; leaves and &lt;em&gt;Curcuma xanthorrhiza &lt;/em&gt;showed reduction of strong HBsAg production from HepG2-NTCP cells with IC&lt;sub&gt;50&lt;/sub&gt; values of 170.48 and 270.51 μg/mL, respectively. Treatment of HepAD38.7-Tet cells with &lt;em&gt;P. niruri &lt;/em&gt;and &lt;em&gt;C. xanthorhiza &lt;/em&gt;at the highest concentration while avoiding cytotoxicity reduced extracellular HBV DNA levels by 70% and 30 % of the untreated control respectively. &lt;strong&gt;Conclusion: &lt;/strong&gt;&lt;em&gt;P. niruri &lt;/em&gt;inhibited both the entry and HBV replication, thus &lt;em&gt;P. niruri &lt;/em&gt;is a promising candidate for anti-HBV drug development.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">5</style></issue><work-type><style face="normal" font="default" size="100%">Research Article</style></work-type><section><style face="normal" font="default" size="100%">1108</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Tutik Sri Wahyuni&lt;sup&gt;1,2,&lt;/sup&gt;*, Adita Ayu Permanasari&lt;sup&gt;2&lt;/sup&gt;, Aty Widyawaruyanti&lt;sup&gt;1,2,&lt;/sup&gt; Hak Hotta&lt;sup&gt;3,4&lt;/sup&gt;, Chie Aoki-Utsubo&lt;sup&gt;4&lt;/sup&gt;, Achmad Fuad Hafid&lt;sup&gt;1,2 &lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Jl. Mulyorejo, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Institute of Tropical Disease, Universitas Airlangga, Jl. Mulyorejo, Surabaya 60115, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;3&lt;/sup&gt;Faculty of Clinical Nutrition and Dietetics, Konan Women’s University, 6-2-23 Morikitamachi, Higashinada-ku, Kobe 658-0001, JAPAN.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Public Health, Kobe University Graduate School of Health Sciences, 7-10-2, Tomogaoka, Suma-ku, Kobe 654-0142, JAPAN.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Fendi Yoga Wardana</style></author><author><style face="normal" font="default" size="100%">Defi Kartika Sari</style></author><author><style face="normal" font="default" size="100%">Myrna Adianti</style></author><author><style face="normal" font="default" size="100%">Adita Ayu Permanasari</style></author><author><style face="normal" font="default" size="100%">Lidya Tumewu</style></author><author><style face="normal" font="default" size="100%">Tomoyoshi Nozaki</style></author><author><style face="normal" font="default" size="100%">Aty Widyawaruyanti</style></author><author><style face="normal" font="default" size="100%">Achmad Fuad Hafid</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">In vitro Anti-Amebic Activity of Cage Xanthones from Cratoxylum sumatranum Stem Bark Against Entamoeba histolytica</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Amoebiasis</style></keyword><keyword><style  face="normal" font="default" size="100%">Bioactivity-guided isolation</style></keyword><keyword><style  face="normal" font="default" size="100%">Cratoxylum sumatranum</style></keyword><keyword><style  face="normal" font="default" size="100%">Entamoeba histolytica</style></keyword><keyword><style  face="normal" font="default" size="100%">NAD kinase</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">May 2020</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">12</style></volume><pages><style face="normal" font="default" size="100%">452-458</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Background:&lt;/strong&gt; Amoebiasis is caused by&lt;em&gt; Entamoeba histolytica,&lt;/em&gt; which is a pathogenic species living on human colon tissues. The development of new drugs for anti-amebic are still very needed for clinical treatment. &lt;strong&gt;Objective: &lt;/strong&gt;This aims to identify the compounds in &lt;em&gt;Cratoxylum sumatranum&lt;/em&gt; for their anti-amoeba activity. &lt;strong&gt;Materials and Methods: &lt;/strong&gt;In this study we used bioactivity-guided isolation and structural analysis to identified anti-amebic compounds from dichloromethane extract of &lt;em&gt;Cratoxylum sumatranum&lt;/em&gt; stem bark. Their anti-amebic activity was determined by an &lt;em&gt;in vitro&lt;/em&gt; cell-based assay against&lt;em&gt; Entamoeba histolytica &lt;/em&gt;and an enzymatic assay on NAD kinase.&lt;strong&gt; Results:&lt;/strong&gt; Two known compounds from the cage xanthone groups, namely cochinchinoxanthone (1) and cochinchinone D (2), were isolated. The structures of the cage xanthone compounds were established by extensive spectroscopic data analysis. Compound (1) showed the greatest level of anti-amebic activity both in cell-based and enzymatic assay, yielding IC&lt;sub&gt;50&lt;/sub&gt; values of 4.57 and 12.17 μg/mL, respectively. In contrast, compound (2) yielded IC&lt;sub&gt;50&lt;/sub&gt; values of 5.19 and 12.60 μg/mL, respectively. Conclusion: When considering the demonstrated anti-amebic activities, it becomes apparent that these compounds, isolated from &lt;em&gt;Cratoxylum sumatranum &lt;/em&gt;stem bark, have the potential to be further developed into effective anti-amebic medicine against &lt;em&gt;Entamoeba histolytica.&lt;/em&gt;&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">3</style></issue><work-type><style face="normal" font="default" size="100%">Original Article</style></work-type><section><style face="normal" font="default" size="100%">452</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Fendi Yoga Wardana&lt;sup&gt;1&lt;/sup&gt;, Defi Kartika Sari&lt;sup&gt;2&lt;/sup&gt;, Myrna Adianti&lt;sup&gt;2,3&lt;/sup&gt;, Adita Ayu Permanasari&lt;sup&gt;2&lt;/sup&gt;, Lidya Tumewu&lt;sup&gt;2&lt;/sup&gt;, Tomoyoshi Nozaki&lt;sup&gt;4&lt;/sup&gt;, Aty Widyawaruyanti&lt;sup&gt;2,5&lt;/sup&gt;, Achmad Fuad Hafid&lt;sup&gt;2,5,&lt;/sup&gt;* &lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Graduate Program of Pharmaceutical Sciences, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Natural Product Medicine Research and Development, Institute of Tropical Disease, Universitas Airlangga, Surabaya, 60115, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Health, Faculty of Vocational Education, Universitas Airlangga, Surabaya, 60115, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Department of School of International Health, Laboratorium of Biomedical Chemistry, The University of Tokyo, Tokyo, 113-0033, JAPAN.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;5&lt;/sup&gt;Department of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya, 60115, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>